Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 409 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 84% confidence The document is a London Stock Exchange RNS announcement disclosing the Company’s total issued share capital and voting rights under FCA DTR 5.6.1. It is a brief regulatory notice rather than a full report or a meeting result. It does not include financial statements, voting results, or proxy materials, but is a general compliance announcement. This fits the fallback Regulatory Filings (RNS) category.
2026-05-29 English
Grant of Share Options
Director's Dealing Classification · 100% confidence The document is an announcement from Shield Therapeutics plc regarding the grant of share options to the CEO under the company's Retention and Performance Share Plan. It details the number of options granted, the vesting date, and the nature of the transaction. The document is a regulatory announcement about a director's dealing in company shares, specifically the grant of share options to a person discharging managerial responsibility (PDMR). It does not contain financial statements, earnings data, or detailed management discussion. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief report publication announcement or a regulatory filing of another type.
2026-05-05 English
Q1 2026 Trading Update
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q1 2026 Trading Update' and provides unaudited financial metrics for the first quarter of 2026, including net revenues, EBIT, and business updates. It also announces a CFO transition and includes detailed operational and financial performance commentary. The document is approximately 9,241 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. It is not merely an announcement of a report or a certification. The content fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with substantive financial data and analysis. Therefore, the appropriate classification is IR with high confidence. Q1 2026
2026-05-01 English
Total Voting Rights
Regulatory Filings Classification · 95% confidence The document is titled 'Total Voting Rights' and dated 30 April 2026. It provides the total number of ordinary shares issued by Shield Therapeutics plc and states that no shares are held in treasury. It references compliance with the FCA's Disclosure and Transparency Rule 5.6.1, which relates to disclosure of voting rights. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement about the company's share capital and voting rights, not a full report or financial filing. The length is about 5000 characters, and the content is consistent with a Regulatory Filing (RNS) type, which is a general regulatory announcement that does not fit other specific categories.
2026-04-30 English
Enrollment in Phase II Clinical Trial for ACCRUFeR
Regulatory Filings Classification · 90% confidence The document is an RNS (Regulatory News Service) announcement by Shield Therapeutics plc posted on the London Stock Exchange. It describes the commencement of a Phase II clinical trial, provides background on the drug, and includes contact details and boilerplate company information. It is not an AGM presentation, financial report, earnings release, management discussion, or investor presentation. It is a generic regulatory press release, which falls under the Regulatory Filings category (RNS).
2026-04-27 English
Audited results for year ended 31 December 2025
Earnings Release Classification · 90% confidence The document is an RNS press release titled “Audited results for the year ended 31 December 2025” containing an overview of financial highlights, CEO and Chairman statements, detailed financial review, segment performance, and host of operational and regulatory updates. It is not the full Annual Report (10-K), as indicated by the statement that the Annual Report & Notice of AGM will be published separately. Instead it represents the initial full-year earnings announcement (preliminary audited results). Therefore it best fits the definition of an Earnings Release (ER). FY 2025
2026-04-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.